March 14, 2019 C-Path, FNIH Announce Clinical Development User’s Guide for Kidney Safety Biomarkers TUCSON, Ariz., March 14, 2019 — The Critical Path Institute’s (C-Path) Predictive Safety Testing Consortium (PST
March 10, 2019 Directional inconsistency between Response Evaluation Criteria in Solid Tumors (RECIST) time to progression and response speed and depth
February 27, 2019 C-Path and FARA Launch Friedreich’s Ataxia Integrated Clinical Database to Advance the Development of Treatments for FA TUCSON, Ariz. and DOWNINGTOWN, Penn., February 27, 2019 — Critical Path Institute’s (C-Path) Data Collaboration Center (DCC) a
February 23, 2019 Investigating the Value of Urine Volume, Creatinine, and Cystatin C for Urinary Biomarkers Normalization for Drug Development Studies
February 19, 2019 Delving into the Role of Public Private Partnerships in Shaping the Landscape to Enable Precision Medicine for Neurodegeneration | 7th World CNS Summit, Boston, MA
February 8, 2019 Regulatory strategies for rare diseases under current global regulatory statutes: a discussion with stakeholders
January 17, 2019 Critical Path Institute Celebrates Expanded Operations with Opening of European Headquarters C-Path in the EU will work to accelerate the development of new therapies through innovative methodologies for endorsement
January 8, 2019 Flinn Foundation Awards Critical Path Institute and TGen North a New Grant to Develop and Pilot a System to Respond to Antimicrobial Resistance TUCSON, Ariz., January 8, 2019 — Critical Path Institute (C-Path) and Flagstaff, Arizona-based TGen North — the Pathogen and M
